Overall N=100 | ||
Patient demographics | ||
Age, years | Mean (SD) | 77.0 (6.5) |
Median (min, max) | 77.0 (57, 90) | |
Sex, male | n (%) | 45 (45.0) |
Baseline characteristics | ||
AMD location, n (%) | Subfoveal | 90 (90.0) |
Extrafoveal | 7 (7.0) | |
Not gradable | 3 (3.0) | |
CNV subtype, n (%) | Predominantly classic | 12 (12.0) |
Minimal classic | 3 (3.0) | |
Occult (no RAP, no PCV) | 71 (71.0) | |
Occult – RAP | 2 (2.0) | |
Occult – PCV | 0 (0.0) | |
RPE tear | 0 (0.0) | |
Not gradable | 10 (10.0) | |
Disciform scar | 2 (2.0) | |
CSRT, μm | Mean (SD) | 409.41 (142.8) |
Median (min, max) | 384.00 (154.0, 975.0) | |
BCVA in the study eye, letters | Mean (SD) | 68.7 (12.65) |
Median (min, max) | 71.5 (36, 90) | |
Treatment history | ||
Duration of aflibercept treatment prior to switch, days* | Mean (SD) | 325.5 (160.0) |
Median (min, max) | 295.5 (63, 933) | |
Number of aflibercept injections received | Mean (SD) | 7.8 (3.0) |
Median (min, max) | 7.0 (3, 16) | |
Aflibercept retreatment interval, days† | Mean (SD) | 47.16 (8.4) |
Median (min, max) | 47.25 (31.0, 81.9) |
Full analysis set.
*Duration=date of last aflibercept injection–date of first aflibercept injection+1
†Retreatment interval=(date of last aflibercept injection–date of first aflibercept injection) / (total number of aflibercept injections–1), defined only for patients with >1 aflibercept injections. The retreatment interval for the monthly and bimonthly data were collected together.
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CSRT, central subfield retinal thickness; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; RPE, retinal pigment epithelium.